Latest stories on RNAZ
TransCode Therapeutics Shareholders Approve Key Capital Measures
TipRanks50 · neutralgeneral
Transcode Therapeutics, Inc. (RNAZ) files 8-K
SEC 8-K50 · neutralgeneral
TransCode Therapeutics Updates Preferred Stock Ownership Limits
TipRanks50 · neutralgeneral
Transcode Therapeutics, Inc. (RNAZ) files 8-K
SEC 8-K50 · neutralgeneral
TransCode Adjourns Annual Meeting Amid Nasdaq Listing Steps
TipRanks50 · neutralgeneral
Transcode Therapeutics, Inc. (RNAZ) files 8-K
SEC 8-K50 · neutralgeneral
TransCode Highlights Progress of Lead RNA Cancer Therapeutic
TipRanks63 · neutralproduct/pr
Transcode Therapeutics, Inc. (RNAZ) files 8-K
SEC 8-K50 · neutralgeneral
TransCode Therapeutics to Host R&D Webcast on June 18, 2026 | RNAZ Stock News
StockTitan56 · neutralproduct/pr
TransCode Therapeutics to Host R&D Webcast on June 18, 2026
PR Newswire56 · neutralproduct/pr
TransCode Therapeutics Advances TTX-MC138 After Positive Phase 1a
TipRanks67 · bullishproduct/pr
TransCode Sets Key Deadlines for 2026 Shareholder Meeting
TipRanks50 · neutralgeneral
TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer
PR Newswire63 · neutralproduct/pr
TransCode Therapeutics Receives Nasdaq Listing Deficiency Notice
TipRanks34 · bearishgeneral